Fresenius Medical Care (NYSE:FMS) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Fresenius Medical Care (NYSE:FMS) in a research note issued to investors on Monday. The firm issued a strong-buy rating on the stock.

Separately, Truist Financial decreased their target price on shares of Fresenius Medical Care from $24.00 to $22.00 and set a hold rating on the stock in a research report on Wednesday, July 31st. One analyst has rated the stock with a sell rating, two have assigned a hold rating, one has given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Fresenius Medical Care currently has an average rating of Hold and an average target price of $22.00.

Fresenius Medical Care Stock Down 1.8 %

FMS opened at $20.75 on Monday. The company has a market cap of $12.18 billion, a price-to-earnings ratio of 23.31, a PEG ratio of 1.08 and a beta of 0.90. Fresenius Medical Care has a one year low of $16.37 and a one year high of $22.76. The business’s fifty day moving average is $19.76 and its two-hundred day moving average is $19.99. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.09 and a current ratio of 1.46.

Fresenius Medical Care (NYSE:FMS) last posted its quarterly earnings data on Tuesday, July 30th. The company reported $0.38 EPS for the quarter, meeting analysts’ consensus estimates of $0.38. Fresenius Medical Care had a return on equity of 5.48% and a net margin of 2.72%. The business had revenue of $5.13 billion for the quarter, compared to analyst estimates of $5.28 billion. Analysts anticipate that Fresenius Medical Care will post 1.51 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. GAMMA Investing LLC lifted its position in shares of Fresenius Medical Care by 21.8% during the first quarter. GAMMA Investing LLC now owns 4,230 shares of the company’s stock worth $82,000 after purchasing an additional 758 shares in the last quarter. ORG Partners LLC purchased a new position in Fresenius Medical Care in the 1st quarter valued at about $110,000. SageView Advisory Group LLC acquired a new stake in shares of Fresenius Medical Care during the first quarter valued at about $127,000. Signaturefd LLC lifted its stake in shares of Fresenius Medical Care by 8.4% in the second quarter. Signaturefd LLC now owns 8,713 shares of the company’s stock worth $166,000 after acquiring an additional 672 shares in the last quarter. Finally, Kimelman & Baird LLC acquired a new stake in Fresenius Medical Care during the 2nd quarter valued at approximately $186,000. 8.25% of the stock is owned by institutional investors and hedge funds.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.